Dr. Salles on Improving Immune Respone in Follicular Lymphoma

Gilles A. Salles, MD, PhD
Published: Tuesday, Feb 14, 2017



Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti–PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.

This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.
 


Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti–PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.

This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x